Kemin Industries has acquired Hennessy Research Associates, strengthening its position in animal health with expertise in veterinary vaccines and biological manufacturing. The move adds contract research, development and manufacturing capabilities to Kemin’s growing global portfolio.
Kemin Industries announced the acquisition of Hennessy Research Associates, a Kansas-based contract research and development company specialized in vaccines for infectious animal diseases. The deal broadens Kemin’s animal health solutions by incorporating vaccine innovation and manufacturing know-how into its operations.
Dr. Chris Nelson
“With this acquisition, we strengthen our position in the U.S. and global animal health markets with additional expertise and science-backed research,” said Dr. Chris Nelson, President and CEO of Kemin Industries. He underlined that the move will help ensure the health and welfare of animals worldwide.
Founded in 2001 by Dr. Kristina J. Hennessy, the company has built a strong reputation in vaccine R&D, immunology, and biological process development. Dr. Hennessy, who will continue to work with the team under Kemin, described the transaction as a “transformational time” for advancing animal vaccine innovations.
Hennessy Research Associates, with its 50 scientists and technical experts, will operate within Kemin as a Contract Research Organization, Contract Development and Manufacturing Organization, and Contract Manufacturer. The acquisition expands the scope of Kemin Biologics, which already provides cost-effective vaccine development and manufacturing for the global animal health industry.
Kemin, established in 1961 and active in more than 120 countries, is widely known in the feed sector for its additives and nutritional solutions.